Enanta Pharmaceuticals, Inc. (ENTA)

In the past six months, Enanta Pharmaceuticals' stock has increased by 40.90%. Key events include the announcement of fiscal first quarter results, pipeline advancements and data presentations, a public stock offering, and a lawsuit against Pfizer in the European Union over its Paxlovid Covid-19 drug.

Detailed information on the demand seasonality for Enanta Pharmaceuticals' specific products and services is not publicly available. Demand for RSV therapeutics would likely exhibit seasonality, with higher demand during the typical RSV season. The demand for HCV treatments is likely less seasonal, while demand for treatments for chronic immunological conditions is generally not seasonal. Demand for HBV treatments would likely be non-seasonal, and for human coronaviruses, demand could be seasonal depending on the specific virus and its prevalence patterns.

Enanta Pharmaceuticals, Inc., a clinical-stage biotechnology company in Watertown, Massachusetts, specializes in discovering and developing novel, small-molecule drugs for viral infections and immunological diseases, operating within the Healthcare sector. Enanta's product pipeline includes HCV treatments through collaborations with AbbVie, RSV treatments like zelicapavir and EDP-323, immunology programs targeting inflammatory diseases, and preclinical candidates against HBV and human coronaviruses.

Enanta Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts, where its corporate offices and research and development operations are located. Its discovered HCV protease inhibitors are commercialized globally by AbbVie under the tradenames MAVYRET® and MAVIRET®.

Enanta Pharmaceuticals generally maintains a positive brand reputation within the biotechnology sector, driven by its scientific expertise and pipeline advancements. The company has a "Moderate Buy" consensus rating from analysts. Positive events include the advancement of its RSV and immunology pipelines, positive Phase 2b results for zelicapavir, presentations of promising data at scientific conferences, and the ongoing revenue stream from its collaboration with AbbVie. A lawsuit filed against Pfizer in the European Union concerning the Paxlovid Covid-19 drug could be perceived as impacting its reputation.

As of May 4, 2026, institutional investors hold a significant portion of Enanta Pharmaceuticals' stock, with 94.99% held by institutions and 11.48% by insiders. Major institutional owners include Janus Henderson Group Plc and BlackRock, Inc. Individual insiders who own company stock include Jay R. Luly and Yat Sun Or.